Personalized Radiation Therapy for Glioblastoma
Trial Summary
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Personalized Radiation Therapy for Glioblastoma?
Research suggests that using advanced radiation techniques like hypofractionated radiotherapy and stereotactic radiosurgery can help improve local control of glioblastoma, which may lead to better outcomes. Additionally, combining full-dose external beam radiotherapy with other methods like brachytherapy or radiosurgery boosts has shown an increase in median survival for selected patients.12345
Is Personalized Radiation Therapy safe for humans?
Research on different forms of radiation therapy for glioblastoma, like stereotactic radiosurgery and hypofractionated radiotherapy, suggests that while these treatments aim to improve outcomes, they also focus on maintaining quality of life and limiting side effects. However, the safety and effectiveness can vary, and it's important to discuss potential risks with your healthcare provider.16789
How is Personalized Radiation Therapy different from other treatments for glioblastoma?
Personalized Radiation Therapy for glioblastoma is unique because it uses lower doses of radiation tailored to the individual, aiming to reduce damage to healthy brain tissue while still effectively targeting the tumor. This approach contrasts with standard treatments that use higher, uniform doses, which can lead to more side effects without improving survival.28101112
What is the purpose of this trial?
This trial is testing if giving customized higher doses of radiation can help patients with aggressive brain cancer live longer without their disease getting worse. The study will also look at side effects and overall survival.
Research Team
Michelle Alonso-Basanta
Principal Investigator
Abramson Cancer Center at Penn Medicine
Eligibility Criteria
This trial is for adults over 18 with a confirmed diagnosis of WHO Grade IV glioblastoma who have had most of their tumor surgically removed and are set to receive chemoradiation. Participants must be able to consent and have a Karnofsky Performance Status (KPS) score of at least 70, indicating they can care for themselves.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Radiation
Participants receive personalized dose-escalated radiation therapy
Follow-up
Participants are monitored for safety, toxicity, patterns of recurrence, and overall survival
Treatment Details
Interventions
- Personalized Radiation Therapy
Personalized Radiation Therapy is already approved in United States, European Union for the following indications:
- HPV-positive throat cancer
- HPV-positive oropharyngeal squamous cell carcinoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Abramson Cancer Center of the University of Pennsylvania
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Lead Sponsor